<DOC>
	<DOCNO>NCT01913353</DOCNO>
	<brief_summary>To demonstrate efficacy MVA-BN® showing vaccination prior administration ACAM2000® result attenuate take .</brief_summary>
	<brief_title>A Non-inferiority Trial Compare MVA-BN® Smallpox Vaccine ACAM2000®</brief_title>
	<detailed_description>To demonstrate efficacy MVA-BN® assess non-inferiority MVA-BN® compare ACAM2000® term vaccinia-specific Plaque Reduction Neutralization Test ( PRNT ) antibody response Peak Visits ( Day 42 Group 1 Day 28 Group 2 ) show vaccination MVA-BN® prior administration ACAM2000® result attenuation take .</detailed_description>
	<mesh_term>Vaccinia</mesh_term>
	<mesh_term>Smallpox</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Healthy male female subject , 1842 year age 2 . The subject read , sign date Informed Consent , advise risk benefit trial language understood subject prior performance trial specific procedure 3 . Acceptable medical history screen evaluation physical examination 4 . BMI great eaqual 18.5 samller 35 5 . Women childbearing potential ( WOCBP ) must negative serum pregnancy test Screening negative urine serum pregnancy test within 24 hour prior vaccination 6 . WOCBP must use acceptable method contraception 28 day prior first vaccination , must agree use acceptable method contraception trial , must avoid become pregnant least 28 day last vaccination . A woman consider childbearing potential unless postmenopausal surgically sterilize . ( Acceptable contraception method restrict abstinence , barrier contraceptive , intrauterine contraceptive device license hormonal product ) 7 . Human Immunodeficiency Virus ( HIV ) antibody negative , hepatitis B surface antigen negative negative antibody test hepatitis C virus 8 . White blood cell great eaqual 2500/mm3 small 11,000/mm3 9 . Hemoglobin within normal limit 10 . Platelets great eaqual low normal limit 11 . Adequate renal function define calculated Creatinine Clearance ( CrCl ) great 60 ml/min estimate CockcroftGault equation 12 . Adequate hepatic function absence evidence significant liver disease define : Total bilirubin great 1.5 x Upper Limit Normal ( ULN ) Alanine Aminotransferase ( ALT ) , Aspartate Aminotransferase ( AST ) great 1.5 x ULN Alkaline Phosphatase ( Alk Phos ) great 1.5 x ULN 13 . Troponin I small 2 x ULN 14 . Electrocardiogram ( ECG ) without clinically significant finding , e.g . kind atrioventricular intraventricular condition block complete left right bundle branch block , atrioventricular node block , QTc PR prolongation , premature atrial contraction atrial arrhythmia , sustain ventricular arrhythmia , two premature ventricular contraction row , ST elevation consistent ischemia 1 . Pregnant breastfeed woman 2 . Typical vaccinia scar 3 . Known suspected history smallpox vaccination define visible vaccination scar documentation smallpox vaccination report subject 4 . History vaccination poxvirusbased vaccine 5 . History serious medical condition , opinion investigator would compromise safety subject 6 . History active immunodeficiency immunosuppression cause acquired congenital disease cause ongoing treatment chronic ( great 14 day ) highdose corticosteroid ( small 5 mg prednisone [ equivalent ] per day apply systemically , i.e . parenterally orally ) , chronic plan treatment steroid eye drop ointment time enrollment radiation , immunosuppressive drug ; lowdose corticosteroid topical product nasal spray use sporadically , i.e . pro nata ( accord circumstance ) permissible 7 . Having radiation Xray treatment ( routine Xrays ) within last 3 month 8 . Post organ bonemarrow transplant subject whether receive chronic immunosuppressive therapy 9 . Eye surgery within 4 week prior trial vaccination 10 . History active autoimmune disease . Persons vitiligo thyroid disease take thyroid hormone replacement exclude 11 . Uncontrolled serious infection , i.e . respond antimicrobial therapy 12 . History malignancy , squamous cell basal cell skin cancer , unless surgical excision consider achieved cure . Subjects history skin cancer must vaccinate previous site cancer 13 . History keloid formation 14 . History clinical manifestation severe hematological , renal , hepatic , pulmonary , central nervous , cardiovascular gastrointestinal disorder 15 . History coronary heart disease , myocardial infarction , angina , congestive heart failure , cardiomyopathy , stroke transient ischemic attack , uncontrolled high blood pressure , heart condition care doctor 16 . Chest pain ( diagnosed cardiac relate ) trouble breathe exertion 17 . Ten percent great risk develop myocardial infarction coronary death within next 10 year use National Cholesterol Education Program 's Risk Assessment Tool : http : //hin.nhlbi.nih.gov/atpiii/calculator.asp NOTE : This criterion apply subject 20 year age old 18 . History immediate family member ( father , mother , brother , sister ) onset ischemic heart disease age 50 year 19 . Clinically significant psychological disorder adequately control medical treatment 20 . Active history chronic alcohol abuse and/or intravenous and/or nasal drug abuse ( within past 6 month ) 21 . History anaphylaxis severe allergic reaction serious adverse reaction vaccine 22 . Eczema degree history eczema 23 . People active atopic dermatitis ( AD ) [ characterize pruritus , eczematous lesion , xerosis ( dry skin ) , lichenification ( thicken skin increase skin marking ] history AD 24 . People chronic exfoliative skin disorders/conditions 25 . People active current Varicella zoster , Herpes zoster , impetigo , uncontrolled acne , Darier 's disease acute skin disorder large magnitude , e.g. , laceration require suture 26 . People tattoo cover vaccination injection area ( prevent assessment area interfere vaccination site photograph ) 27 . Having receive vaccination plan vaccination live vaccine within 28 day prior trial vaccination 28 . Having receive vaccination plan vaccination kill vaccine within 14 day prior trial vaccination 29 . Administration plan administration immunoglobulin and/or blood product period start three month prior administration vaccine end trial conclusion 30 . Use investigational nonregistered drug vaccine trial vaccine within 28 day precede first dose trial vaccine plan administration drug /vaccine trial period 31 . Blood donation duration trial 32 . Acute disease ( illness without fever ) time enrollment 33 . Temperature ≥ 100.4°F ( 38.0°C ) time enrollment 34 . Known household contact , occupational exposure ( minimal contact ) following : Pregnant woman Children &lt; 12 month age People eczema history eczema People active AD history AD People chronic exfoliative skin disorders/conditions People active Varicella zoster , Herpes zoster , impetigo , uncontrolled acne , Darier 's disease acute skin disorder large magnitude , e.g. , laceration require suture , burn area great 2×2 cm People active recent immunodeficiency disease use immunosuppressive medication , example : take medication HIV , AIDS , leukemia , lymphoma , chronic liver problem , take medication Crohn 's disease , lupus , arthritis , immune disease ; radiation Xray treatment ( routine Xrays ) within last 3 month ; ever bonemarrow organ transplant ( take medication ) ; another problem require steroid , prednisone cancer drug treatment People eye surgery within last 4 week 35 . Known allergy MVABN® vaccine constituent , e.g . tris ( hydroxymethyl ) amino methane , include know allergy egg aminoglycoside ( gentamycin ) 36 . Known allergy ACAM2000® diluent include polymyxin B sulfate , neomycin sulfate , phenol 37 . Known allergy vaccinia immunoglobulin ( VIG ) include thimerosal previous allergic reaction immunoglobulins 38 . Known allergy cidofovir , sulfa drug , probenecid 39 . Trial personnel</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>42 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>